Bibliografia UJ CM

1/8
Franck Morschhauser, Herve Tilly, Aristeidis Chaidos, Pamela McKay, Tycel Phillips, Sarit Assouline, Connie Lee Batlevi, Phillip Campbell, Vincent Ribrag, Gandhi Laurent Damaj, Michael Dickinson, Wojciech Jurczak, Maciej Kazmierczak, Stephen Opat, John Radford, Anna Schmitt, Jay Yang, Jennifer Whalen, Shefali Agarwal, Deyaa Adib, Gilles Salles.
Tazemetostat for patients with relapsed or refractory follicular lymphoma : an open-label, single-arm, multicentre, phase 2 trial.
Lancet. Oncology
2020 : Vol. 21, nr 11, s. 1433-1442, il., bibliogr. 30 poz., sum.
Autor korespondencyjny: Franck Morschhauser.
p-ISSN: 1470-2045
AZ
ORG
AIF
IF: 41.316
Adres url:
Streszczenie w PubMed:
2/8
Michael Wang, Simon Rule, Pier Luigi Zinzani, Andre Goy, Olivier Casasnova, Stephen D. Smith, Gandhi Damaj, Jeanette K. Doorduijn, Thierry Lamy, Franck Morschhauser, Carlos Panizo, Bijal Shah, Andrew Davies, Richard Eek, Jehan Dupuis, Eric Jacobsen, Arnon P. Kater, Steven Le Gouill, Lucie Oberic, Tadeusz Robak, Preetesh Jain, Melanie M. Frigault, Raquel Izumi, Dorothy Nguyen, Priti Patel, Ming Yin, Monika Długosz-Danecka.
Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma.
Leukemia
2019 : Vol. 33, nr 11, s. 2762-2766, bibliogr. 6 poz.
Autor korespondencyjny: Michael Wang.
Open Access Creative Commons Attribution License CC-BY 4.0.
p-ISSN: 0887-6924
LR
AIF
IF: 8.665
Adres url:
Streszczenie w PubMed:
3/8
Marco Montillo, Arpad Illes, Tadeusz Robak, Alexander S. Pristupa, Malgorzata Wach, Miklos Egyed, Julio Delgado, Wojciech Jurczak, Franck Morschhauser, Anan Schuh, Herebrt Eradat, Sanatan Shreay, Jacqueline C. Barrientos, Andrew D. Zelenetz.
Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients : results of a phase 3, randomized, controlled trial.
Health and Quality of Life Outcomes
2019 : Vol. 17, 173, il., bibliogr. 38 poz., abstr.
Open Access Creative Commons Attribution License CC-BY 4.0.
Autor korespondencyjny: Marco Montillo.
p-ISSN: 1477-7525
AZ
ORG
AIF
IF: 2.344
Adres url:
Streszczenie w PubMed:
4/8
Michael Wang, Simon Rule, Pier Luigi Zinzani, Andre Goy, Olivier Casasnovas, Stephen D. Smith, Gandhi Damaj, Jeanette Doorduijn, Thierry Lamy, Franck Morschhauser, Carlos Panizo, Bijal Shah, Andrew Davies, Richard Eek, Jehan Dupuis, Eric Jacobsen, Arnon P. Kater, Steven Le Gouill, Lucie Oberic, Taduesz Robak, Todd Covey, Richa Dua, Ahmed Hamdy, Xin Huang, Raquel Izumi, Priti Patel, Wayne Rothbaum, J. Greg Slatter, Wojciech Jurczak.
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Lancet
2018 : Vol. 391, nr 10121, s. 659-667, il., bibliogr. 24 poz., sum.
Autor korespondencyjny: Michael Wang.
p-ISSN: 0140-6736
AZ
ORG
AIF
IF: 59.102
Adres url:
Streszczenie w PubMed:
5/8
Luca Arcaini, Thierry Lamy, Jan Walewski, David Belada, Jiri Mayer, Wojciech Jurczak, Franck Morschhauser, Julia Alexeeva, Simon Rule, Jose Cabecadas, Elias Campo, Stefano A. Pileri, Tsvetan Biyukov, Meera Patturajan, Marie-Laure Casadebaig Bravo, Marek Trneny.
Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma
British Journal of Haematology
2018 : Vol. 180, nr 2, s. 224-235, il., bibliogr., sum.
Open Access Creative Commons Attribution License CC-BY-NC-ND 4.0.
Autor korespondencyjny: Luca Arcaini.
p-ISSN: 0007-1048
AZ
ORG
AIF
IF: 5.206
Adres url:
Streszczenie w PubMed:
6/8
Andrew D. Zelenetz, Jacqueline C. Barrientos, Jennifer R. Brown, Bertrand Coiffier, Julio Delgado, Miklós Egyed, Paolo Ghia, Árpad Illes, Wojciech Jurczak, Paula Marlton, Marco Montillo, Franck Morschhauser, Alexander S. Pristupa, Tadeusz Robak, Jeff P. Sharman, David Simpson, Lukas Smolej, Eugen Tausch, Adeboye H. Adewoye, Lyndah K. Dreiling, Yeonhee Kim, Stephan Stilgenbauer, Peter Hillmen.
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet. Oncology
2017 : Vol. 18, nr 3, s. 297-311, il., bibliogr. 22 poz., sum.
Autor korespondencyjny: Andrew D. Zelenetz.
p-ISSN: 1470-2045
AZ
ORG
AIF
IF: 36.418
Adres url:
Streszczenie w PubMed:
7/8
Marek Trneny, Thierry Lamy, Jan Walewski, David Belada, Jiri Mayer, John Radford, Wojciech Jurczak, Franck Morschhauser, Julia Alexeeva, Simon Rule, Boris Afanasyev, Kamil Kaplanov, Antoine Thyss, Alexej Kuzmin, Sergey Voloshin, Kazimierz Kuliczkowski, Agnieszka Giza, Noel Milpied, Caterina Stelitano, Reinhard Marks, Lorenz Trumper, Tsvetan Biyukov, Meera Patturajan, Marie-Laure Casadebaig Bravo, Casadebaig Bravo, Luca Arcaini.
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
Lancet. Oncology
2016 : Vol. 17, nr 3, s. 319-331, il., bibliogr. 28 poz., sum.
p-ISSN: 1470-2045
AZ
ORG
AIF
IF: 33.900
Adres url:
Streszczenie w PubMed:
8/8
Marek Trneny, Thierry Lamy, Jan Walewski, David Belada, Jiri Mayer, John A. Radford, Wojciech Jurczak, Franck Morschhauser, Julia Alexeeva, Simon A. Rule, Boris V. Afanasyev, Kamil Kaplanov, Antoine Thyss, Alexej Kuzmin, Sergey Voloshin, Kazimierz Kuliczkowski, Agnieszka Giza, Noel Milpied, Caterina Stelitano, Reinhard Marks, Lorenz Trumper, Tsvetan Biyukov, Evelyn Barnett, Marie-Laure Casadebaig Bravo, Luca Arcaini.
Outcomes Following Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma Patients at Risk of Bleeding Events Because of Multiple Comorbidities or Treatment: A Post-Hoc Subgroup Analysis of the SPRINT (MCL-002) Trial.
Blood
2016 : Vol. 128, nr 22, s. 2978
58th ASH Annual Meeting & Exposition, San Diego, California, 3-5 December 2016.
p-ISSN: 0006-4971
SZZ
SIF
Adres url:
Wyświetl ponownie stosując format:

Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie | Biblioteka Medyczna UJ